HC Wainwright Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics (NASDAQ:MNPR) had its price target lifted by HC Wainwright from $22.00 to $40.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently issued reports on MNPR. Piper Sandler initiated coverage on Monopar Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price for the company. Rodman & Renshaw started coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company.

Monopar Therapeutics Trading Up 6.3 %

Shares of MNPR opened at $33.67 on Wednesday. The business’s 50-day moving average price is $23.48 and its 200 day moving average price is $12.00. The stock has a market capitalization of $205.39 million, a P/E ratio of -17.09 and a beta of 1.23. Monopar Therapeutics has a 1-year low of $1.54 and a 1-year high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09. On average, research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Buying and Selling at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan purchased 1,550 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was bought at an average cost of $16.25 per share, with a total value of $25,187.50. Following the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.